Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer Read More » July 29, 2024
Tufts Medical Center Becomes First Hospital in Massachusetts to Adopt MOLLI Surgical’s Breast Cancer Technology Read More » July 29, 2024
The Pursuit of Targeted Agents Broadens the HR+  Breast Cancer Treatment Paradigm Read More » June 28, 2024
Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis Read More » June 28, 2024
DESTINY-Breast Trial Portfolio Spotlights Efficacy of T-DXd in Metastatic Breast Cancer Read More » June 28, 2024
Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy Read More » June 14, 2024
Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer Read More » June 14, 2024
Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy Read More » June 14, 2024
Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give Birth Read More » May 23, 2024
